Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153814 | 0.85 | CHRNB2 (0.43) | CHRM4SLC6A7CHRNB4CHRNA3 | |
| SCHEMBL4159672 | 0.83 | NR1H2 (0.43) | CHRM4NR1H2NR1H3 | |
| SCHEMBL4225875 | 0.81 | AKR1C3 (0.40) | CHRM4SLC6A7NR1H2AGTR2NR1H3 | |
| SCHEMBL14159644 | 0.80 | CHRM4 (0.33) | CHRM4SLC6A7CHRNB4CHRNA3GRM1 | |
| SCHEMBL21224830 | 0.78 | SLC6A7 (0.40) | SLC6A7GRM1AGTR2 | |
| SCHEMBL29252729 | 0.77 | AGTR2 (0.48) | CHRM4SLC6A7NR1H2AGTR2NR1H3 | |
| SCHEMBL3325463 | 0.76 | IDO1 (0.42) | CHRNB4CHRNA3 | |
| SCHEMBL4532377 | 0.75 | HTR3A (0.53) | CHRM4 | |
| SCHEMBL23877686 | 0.74 | TRPC6 (0.46) | CHRM4SLC6A7GRM1 | |
| SCHEMBL4749555 | 0.73 | KDM4E (0.42) | SLC6A7GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563582-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | CHRM4 1211/4885SLC6A7 1266/4885CHRNB4 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.